Secarna Pharmaceuticals
https://www.secarna.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Secarna Pharmaceuticals
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice